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among patients. ConClusions: Based on our research among patients we con-
clude that generic substitution is most likely effective drug policy tool, but since 
there are also many negative experiences (own or shared) with generic drugs, GS is 
still considered as alternative treatment.
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objeCtives: The research analyses (i) the individual and interactive effects of 
three pharmaceutical policies (cost-sharing, prescription quotas, therapeutic ref-
erence pricing) on drugs public and private expenditure and volumes, using Italian 
regional policies as a case-study; (ii) the extent to which the long-run effect of poli-
cies on expenditure is mediated by prescribers’/patients’ behaviours. Methods: 
An enriched difference-in-differences model is used. Firstly, policies impact on 
public and private expenditure and volume is separately estimated. Then, the 
hypothesis that the effects of policies on public expenditure are mediated by behav-
iours (transmission mechanism) is tested. As robustness check, a possible reverse 
causality and feedback mechanisms is tested, by switching the mediator and the 
independent variable. Results: The analysis shows (i) that combined policies do 
not necessarily produce a higher impact than policies alone; (ii) a larger impact 
of policies in the short-run, whereas in the long-run the trend is often reversed, 
but not enough to compensate the final impact, which is usually in the expected 
direction; (iii) as for cost-sharing, that its negative impact on public expenditure is 
mainly due to a decrease in volumes than to a shift from public to private expendi-
ture. ConClusions: Despite its limitation, this study has shined a light on the 
impact of policies which are implemented in different time and places, thus cover-
ing an information gap and supporting policy-makers. Some empirical findings 
show also that pharmaceutical policies may have an unintended impact on health: 
e.g. the volumes decrease due to cost-sharing may imply patients under-treatment.
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objeCtives: There is a general consensus on the need for a stronger patient-cen-
teredness, even in HTA processes. In international comparison different ways of 
public participation (citizens, insured and patients) in the decision-making process 
are discussed and tested. The need was recognized, but not yet fully reflected in 
practice. This study describes how preferences can be taken into account in dif-
ferent decision situations and shows how methods of preference measurement/
citizens’ councils are used in an international context to support decision-making 
and understand the importance of various decision-criteria that influence these 
decisions. Methods: A systematic literature review in PubMed/Medline revealed 
95 articles and showed that methods of patients, citizens and policyholder par-
ticipation are manifold. In order to structure the international approaches further, 
international HTA-organizations worldwide were questioned via e-mail in the end of 
2013 on patients and public participation in their countries. Results: 17 out of 126 
contacted organizations answered to these questions. In general, the participation 
efforts extend from qualitative survey of patients’ needs up to the science-based 
documentaries of quantitative patient preferences. The review and the survey of 
the HTA-agencies show that internationally three mechanisms are used to involve 
the public in decision-making bodies: membership of at least one patient representative 
(e.g., Australia, France, Germany), presentation of oral/written comments from patients 
(e.g., Australia, The Netherlands, Great Britain) and the possibility to check the HTA-
reports and the corresponding draft recommendations before publication (e.g., France, 
Germany, Great Britain, New Zealand, USA). ConClusions: The role of the 
patients or citizens seems to be limited to an informal or ad-hoc basis and is mostly 
restricted to consulting activities. In order to achieve a patient-centered health 
technology assessment two ways to sharing information are relevant: the public 
needs information on medical and health policy/economic issues and decision-
maker need information on the patient perspective.
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objeCtives: Diagnosis Related Groups (DRG) like financing method was introduced 
in Hungary in 1993. In addition to DRG based reimbursement, an degressive upper 
ceiling (financial cap) was introduced for hospital reimbursement. The aim of our 
study was to investigate the financial effects of degressive financing method on 
the Hungarian DRG-based hospital financing. Methods: The data in our analysis 
were derived from the nationwide administrative dataset of the National Health 
Insurance Fund Administration (OEP), the only health care financing agency. We 
examined the period between 2011 and 2013. In 2011 and 2012 hospital activity 
over financial cap was reimbursed up to 110% by 30% of DRG base rate, while in 
2013 hospital activity over financial cap was reimbursed up to 104% by 25% of 
DRG base rate. Results: In 2011 hospital activity exceeded the financial cap by 
4.6% with a monthly variation of 1.5% - 6.6%. In 2012 hospital activity exceeded 
the financial cap by 4.2% with a monthly variation of 1.1% - 6.5%. In 2013 hos-
pital activity exceeded the financial cap by 1.9% with a monthly variation of 
1.1% - 2.6%. Between 2011 and 2013 the DRG base rate remained the same (150000 
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objeCtives: New oral Disease Modifying Treatments (DMTs) for Relapsing 
Remitting Multiple Sclerosis (RRMS) were recently introduced in the US. The 
objective of this study was to assess trends in adoption of oral DMTs among 
RRMS patients in the US. Methods: A multi-center retrospective chart-review 
study of RRMS patients was conducted in the US in 4Q2011, 4Q2012, 2Q2013, and 
4Q2013 to collect de-identified data on diagnosis, clinical status, and treatment 
patterns. Neurologists were screened for duration of practice (≥ 3yrs) and patient 
volume (≥ 15 MS patients/mo) and recruited from a large panel to be geographi-
cally representative. Medical charts of next 10 consecutive MS patients were 
abstracted by each neurologist. RRMS patients taking oral, injectable, or infusible 
DMTs were analyzed. Results: 2362 eligible RRMS patient charts were evaluated 
(4Q2011:23%, 4Q2012:25%, 2Q2013:25% & 4Q2013:26%). Use of oral DMTs increased 
four-fold (4Q2011:7%, 4Q2012:9%, 2Q2013:21% & 4Q2013:31%); use of injectable 
DMTs decreased (4Q2011:82%, 4Q2012:78%, 2Q2013:71% & 4Q2013:60%), as did 
use of infusible DMTs (4Q2011:10%, 4Q2012:12%, 2Q2013:7% & 4Q2013:8%). Across 
timeframes, 61%, 27% & 12% of patients were on 1st-line, 2nd-line, and 3rd-line or 
subsequent treatment, respectively. Among 3rd-line or subsequent patients, oral 
DMT use increased from 23% to 59%; use of injectable and infusible DMTs decreased 
from 34% to 16% and 37% to 25%, respectively. Among 2nd-line patients, oral DMT 
use increased from 10% to 46%; use of injectable and infusible DMTs decreased 
from 66% to 37% and 21% to 15%, respectively. Among 1st-line patients, oral DMT 
use increased from 3% to 16%; use of injectable DMTs decreased from 96% to 83% 
and infusible DMT use remained at 1-2%. ConClusions: Oral DMT use increased 
between 4Q2011-4Q2013, predominantly in 2nd or subsequent lines. The impact of 
this observed pattern of reserving new treatment options for later lines warrants 
scrutiny to optimize patient management and alleviate disease burden.
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objeCtives: To examine the level of awareness and interest in the newly setup 
Health Insurance Marketplace under Affordable Care Act in West Virginia state of 
the United States of America. Methods: Primary survey data were collected in 
July/August 2013 from a stratified sampling of West Virginians. A mail survey was 
completed by respondents in a cross-sectional study. Key variables included gen-
eral awareness of the Health Insurance Marketplace and the availability of subsi-
dies, the individual mandate, interest in using the Marketplace, and perceptions 
of respondents’ ability to qualify for financial assistance. Results: Six thousand 
surveys were mailed with a nine-page questionnaire. A total of 1,198 completed 
surveys were returned. Two months prior to launch, awareness of the Health 
Insurance Marketplace was low in WV; yet interest in the Marketplace was higher 
among those most likely to benefit—the insured and residents likely to qualify 
for financial subsidies. West Virginians reported being familiar with the individual 
mandate. ConClusions: Efforts should be increased at the federal, state, and local 
levels among government and non-government organizations to heighten aware-
ness of the Health Insurance Marketplace in WV and, particularly, the availability of 
subsidies. Many, once made aware, expressed interest in learning more.
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objeCtives: Slovakia has from December 2011 new law that defines list of mol-
ecules for mandatory generic substitution. It was one of the cost-containment 
measures applied in the same time at the field of drug policy. We provided research 
on statistically selected sample of patients in Slovakia to detect current attitude, 
knowledge and believes toward generic substitution (GS). Methods: We created 
special questionnaire for patients and distributed it in selected regions in Slovakia. 
From 600 questionaires, we evaluated 432. Questionares were distributed among 
patients visiting pharmacies in 2013/2014 and all patients were older than 20 
years. Results: There were 57% of women in our sample and only 11% from all 
patients had lower than college education. 71% of all patients were using prescrip-
tion drugs regularly and 58% of all patients were familiar with term GS. Suprisingly, 
only 16% from all patients selected co-payment as the key factor influencing their 
decision toward GS. Recommendation of GS in pharmacy or by doctor was selected 
as key factor that influenced patients in choosing GS or generic molecule (40%). 
Second most influential factor was own experience with generic (27%). Only 8% 
of patients believed that GS can decrease overall consumption of drugs. We also 
found out that 36% of patients consider GS as “risky” because of extended number 
of generics available from various unknown companies. There was also a strong 
statistical relationship between gender and positives as well as negatives of GS 
